NAS:GWPH (UK) Also trade in: Germany UK

GW Pharmaceuticals PLC

$ 183.62 0 (0%)
Volume: 315,903 Avg Vol (1m): 428,358
Market Cap $: 5.79 Bil Enterprise Value $: 5.28 Bil
P/E (TTM): 0.00 P/B: 9.08
Earnings Power Value -45.82
Net Current Asset Value 15.78
Tangible Book 19.99
Projected FCF -27.7
Median P/S Value 71.18
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 7/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 85.63
Cash-To-Debt ranked higher than
71.48% of 859 companies
in the Drug Manufacturers - Major industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
GWPH: 85.63
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 17.78, Med: 257.56, Max: 10000
Current: 85.63
17.78
10000
Equity-to-Asset 0.85
Equity-to-Asset ranked higher than
86.93% of 788 companies
in the Drug Manufacturers - Major industry.
Industry Max: 1.78, Med: 0.64, Min: -27.83
GWPH: 0.85
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.4, Med: 0.82, Max: 0.89
Current: 0.85
0.4
0.89
Debt-to-Equity 0.01
Debt-to-Equity ranked higher than
99.50% of 596 companies
in the Drug Manufacturers - Major industry.
Industry Max: 31.22, Med: 0.32, Min: 0.01
GWPH: 0.01
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: 0, Med: 0.01, Max: 0.06
Current: 0.01
0
0.06
Debt-to-EBITDA -0.02
Debt-to-EBITDA ranked lower than
100.00% of 495 companies
in the Drug Manufacturers - Major industry.
Industry Max: 343059.67, Med: 1.92, Min: 0.01
GWPH: -0.02
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -0.22, Med: -0.02, Max: 0.05
Current: -0.02
-0.22
0.05
Piotroski F-Score 5
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 29.71
DISTRESS
GREY
SAFE
Beneish M-Score -1.29
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -349.46%
WACC 17.63%

Profitability & Growth : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -610.47
Operating Margin ranked lower than
94.63% of 801 companies
in the Drug Manufacturers - Major industry.
Industry Max: 8950, Med: 7.97, Min: -232970.37
GWPH: -610.47
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -1925.61, Med: -56.73, Max: 14.66
Current: -610.47
-1925.61
14.66
Net Margin % -570.16
Net Margin ranked lower than
94.26% of 802 companies
in the Drug Manufacturers - Major industry.
Industry Max: 304900, Med: 5.32, Min: -216285.19
GWPH: -570.16
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -1975.42, Med: -32.73, Max: 15.13
Current: -570.16
-1975.42
15.13
ROE % -49.11
ROE ranked lower than
82.93% of 832 companies
in the Drug Manufacturers - Major industry.
Industry Max: 316.96, Med: 5.94, Min: -3119.47
GWPH: -49.11
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -345.19, Med: -15.6, Max: 62.76
Current: -49.11
-345.19
62.76
ROA % -42.80
ROA ranked lower than
85.30% of 871 companies
in the Drug Manufacturers - Major industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
GWPH: -42.8
Ranked among companies with meaningful ROA only.
N/A
ROC (Joel Greenblatt) % -326.68
ROC (Joel Greenblatt) ranked lower than
86.67% of 855 companies
in the Drug Manufacturers - Major industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
GWPH: -326.68
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -947.06, Med: -211.88, Max: 267.49
Current: -326.68
-947.06
267.49
3-Year Total Revenue Growth Rate -43.90
3-Year Revenue Growth Rate ranked lower than
95.21% of 689 companies
in the Drug Manufacturers - Major industry.
Industry Max: 291.9, Med: 5.8, Min: -100
GWPH: -50.6
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
N/A
3-Year Total EBITDA Growth Rate -77.10
3-Year EBITDA Growth Rate ranked lower than
98.15% of 704 companies
in the Drug Manufacturers - Major industry.
Industry Max: 299.6, Med: 7.3, Min: -343.2
GWPH: -56.3
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
N/A
3-Year EPS w/o NRI Growth Rate -70.00
3-Year EPS w/o NRI Growth Rate ranked lower than
97.89% of 663 companies
in the Drug Manufacturers - Major industry.
Industry Max: 385.8, Med: 8.9, Min: -403.2
GWPH: -70
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
N/A

» GWPH's 30-Y Financials

Financials (Next Earnings Date: 2019-08-15)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:GWPH

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Major    NAICS : 0    SIC : 0
Compare TSE:9987 ISX:KLBF SZSE:300146 SHSE:600867 SZSE:002399 TSE:2784 TSE:4536 NSE:TORNTPHARM SZSE:002422 XKRX:008930 LSE:HCM BOM:500087 LSE:DPH SHSE:600572 BOM:500302 BOM:500660 SHSE:600466 HKSE:02186 SZSE:002019 XKRX:000100
Traded in other countries GW2.Germany GWP.UK
Address Sovereign House, Chivers Way, Vision Park, Histon, Cambridge, GBR, CB24 9BZ
GW Pharmaceuticals PLC is a UK based company, engaged in the research, development, and commercialization of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant. Its business activities are functioned through three reportable segments which are Commercial, Sativex Research and Development and Pipeline Research and Development. The company's lead product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol used for the treatment of a number of rare childhood-onset epilepsy disorders. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. Geographically its presence can be seen across the region of UK, Europe, US, Canada, and others.

Ratios

Current vs industry vs history
PB Ratio 9.08
PB Ratio ranked lower than
75.46% of 819 companies
in the Drug Manufacturers - Major industry.
Industry Max: 227.39, Med: 2.64, Min: 0.05
GWPH: 9.08
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 2.17, Med: 6.35, Max: 18.01
Current: 9.08
2.17
18.01
PS Ratio 120.85
PS Ratio ranked lower than
96.52% of 775 companies
in the Drug Manufacturers - Major industry.
Industry Max: 9105.26, Med: 3.1, Min: 0.03
GWPH: 120.85
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 1.53, Med: 46.84, Max: 376.18
Current: 120.85
1.53
376.18
EV-to-EBIT -19.33
EV-to-EBIT ranked lower than
100.00% of 572 companies
in the Drug Manufacturers - Major industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
GWPH: -19.33
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -63.7, Med: -16.25, Max: 154.2
Current: -19.33
-63.7
154.2
EV-to-EBITDA -20.04
EV-to-EBITDA ranked lower than
100.00% of 597 companies
in the Drug Manufacturers - Major industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
GWPH: -20.04
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -69.2, Med: -17, Max: 77.8
Current: -20.04
-69.2
77.8
EV-to-Revenue 109.85
EV-to-Revenue ranked lower than
94.21% of 795 companies
in the Drug Manufacturers - Major industry.
Industry Max: 23858.8, Med: 3.24, Min: 0.03
GWPH: 109.85
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 0.7, Med: 45.05, Max: 362.4
Current: 109.85
0.7
362.4
Current Ratio 7.81
Current Ratio ranked higher than
89.47% of 855 companies
in the Drug Manufacturers - Major industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
GWPH: 7.81
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.75, Med: 6.33, Max: 13.46
Current: 7.81
1.75
13.46
Quick Ratio 7.19
Quick Ratio ranked higher than
89.59% of 855 companies
in the Drug Manufacturers - Major industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
GWPH: 7.19
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 1.7, Med: 6.33, Max: 13.28
Current: 7.19
1.7
13.28
Days Inventory 936.01
Days Inventory ranked lower than
98.41% of 755 companies
in the Drug Manufacturers - Major industry.
Industry Max: 950.68, Med: 119.8, Min: 0.2
GWPH: 936.01
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 299.94, Med: 648.61, Max: 1171.61
Current: 936.01
299.94
1171.61
Days Sales Outstanding 146.31
Days Sales Outstanding ranked lower than
98.83% of 770 companies
in the Drug Manufacturers - Major industry.
Industry Max: 864.61, Med: 81.76, Min: 0.1
GWPH: 146.31
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 1.95, Med: 8, Max: 57.82
Current: 146.31
1.95
57.82
Days Payable 383.70
Days Payable ranked higher than
97.63% of 758 companies
in the Drug Manufacturers - Major industry.
Industry Max: 952.38, Med: 76.32, Min: 0.04
GWPH: 383.7
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 414.96, Med: 635.66, Max: 4325.04
Current: 383.7
414.96
4325.04

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -8.80
3-Year Share Buyback Rate ranked higher than
59.72% of 571 companies
in the Drug Manufacturers - Major industry.
Industry Max: 100, Med: -5.3, Min: -815
GWPH: -8.8
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -23.8, Med: -4.8, Max: -1.1
Current: -8.8
-23.8
-1.1

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 9.18
Price-to-Tangible-Book ranked lower than
66.36% of 749 companies
in the Drug Manufacturers - Major industry.
Industry Max: 972.22, Med: 3.33, Min: 0.05
GWPH: 9.18
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 2.51, Med: 6.54, Max: 66
Current: 9.18
2.51
66
Price-to-Median-PS-Value 2.59
Price-to-Median-PS-Value ranked lower than
100.00% of 743 companies
in the Drug Manufacturers - Major industry.
Industry Max: 238.36, Med: 0.94, Min: 0.01
GWPH: 2.59
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.03, Med: 0.97, Max: 7.76
Current: 2.59
0.03
7.76
Earnings Yield (Joel Greenblatt) % -5.17
Earnings Yield (Greenblatt) ranked lower than
85.24% of 867 companies
in the Drug Manufacturers - Major industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
GWPH: -5.17
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -29.3, Med: -3.9, Max: 6.2
Current: -5.17
-29.3
6.2

More Statistics

Revenue (TTM) (Mil) $ 48.03
EPS (TTM) $ -8.1
Beta 2.64
Volatility % 69.36
52-Week Range $ 90.14 - 196
Shares Outstanding (Mil) 30.72

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 5
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y